DeepMed Research

SWEDISH ORPHAN BIOVITRUM

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2010-01-01

Employees: -

Market Cap: $10.7B

Website: http://www.sobi.com/

Clinical Trials

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

Phase 4

Not yet recruiting

Conditions: Hemophilia A

Interventions: Drug: Efanesoctocog alfa

First Posted Date: 2025-04-23

Last Posted Date: 2025-04-23

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 250

Registration Number: NCT06940830

Locations: 🇩🇪
Sobi Investigational Site, Frankfurt am main, Germany

A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis

Phase 4

Recruiting

Conditions: Haemophilia A (Moderate or Severe)
Hemophilia, Classic
Haemophilia
Hemophilia
Classic Hemophilia
Synovial Hypertrophy

Interventions: Drug: Efanesoctocog alfa

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-26

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 35

Registration Number: NCT06752850

Locations: 🇸🇪
Sobi Investigational Site, Malmö, Sweden

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

Phase 2

Recruiting

Conditions: VEXAS
VEXAS Syndrome

Interventions: Drug: Placebo
Drug: Pacritinib

First Posted Date: 2025-01-17

Last Posted Date: 2025-05-13

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 78

Registration Number: NCT06782373

Locations: 🇫🇷
Tenon Hospital - APHP, Paris, France
🇫🇷
Hospices Civils de Lyon - Lyon Sud, Pierre-Bénite, France
🇺🇸
Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States

and more 37 locations

Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

Phase 3

Recruiting

Conditions: Severe Haemophilia A

Interventions: Drug: Efanesoctocog alfa

First Posted Date: 2024-12-04

Last Posted Date: 2025-04-09

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 78

Registration Number: NCT06716814

Locations: 🇪🇸
Sobi Investigational Site, Zaragoza, Spain

A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF

Phase 4

Not yet recruiting

Conditions: Familial Mediterranean Fever (FMF )

Interventions: Drug: Anakinra

First Posted Date: 2024-10-30

Last Posted Date: 2025-03-03

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 3

Registration Number: NCT06666335

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

Phase 1

Recruiting

Conditions: Hemophilia A

Interventions: Drug: Efanesoctocog alfa

First Posted Date: 2024-08-30

Last Posted Date: 2025-04-03

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 24

Registration Number: NCT06579144

Locations: 🇩🇪
Sobi Investigational site, Frankfurt, Germany
🇪🇸
Sobi Investigational Site, Zaragoza, Spain

Assessment of Macrophage Activation syndromE in STill's Disease

Completed

Conditions: Stills Disease, Juvenile-Onset
Still's Disease, Adult-Onset
Macrophage Activation Syndrome

First Posted Date: 2024-05-08

Last Posted Date: 2024-10-21

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 75

Registration Number: NCT06405152

Locations: 🇪🇸
Swedish Orphan Biovitrum Research Site, Barcelona, Spain

A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients

Recruiting

Conditions: Hereditary Tyrosinemia, Type I

Interventions: Drug: Nitisinone

First Posted Date: 2024-01-26

Last Posted Date: 2025-04-01

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 15

Registration Number: NCT06227429

Locations: 🇨🇳
Swedish Orphan Biovitrum Research Site, Wuhan, China

Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis

Completed

Conditions: Hemophagocytic Lymphohistiocytoses

Interventions: Other: Blood Draws Data Collection

First Posted Date: 2023-09-21

Last Posted Date: 2023-09-21

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 14

Registration Number: NCT06047210

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa

Phase 4

Terminated

Conditions: Hemophilia A
Hemophilia B

Interventions: Procedure: Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)
Other: Haemophilia Joint Health Score (HJHS)

First Posted Date: 2023-05-12

Last Posted Date: 2025-03-25

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 10

Registration Number: NCT05856266

Locations: 🇸🇮
Study site 147, Ljubljana, Slovenia
🇮🇪
Study site 133, Dublin, Ireland
🇨🇿
Study site 105, Praha, Czechia

and more 53 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy